BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Fish and Richardson
Cantor Fitzgerald

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,034,230

« Back to Dashboard

Summary for Patent: 5,034,230

Title: Anti-allergic ophthalmics
Abstract:This invention relates to low irritative ophthalmics containing the compound of the formula or salts thereof which are useful for treatment of anti-allergic eye diseases such as allergic conjunctivitis ##STR1##
Inventor(s): Morita; Takakazu (Toyonaka, JP), Iso; Tadashi (Kawachinagano, JP), Kawashima; Youichi (Kyoto, JP), Hikida; Mitsushi (Takatsuki, JP)
Assignee: Santen Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:07/392,922
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,034,230

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan62-331025Dec 25, 1987
PCT Information
PCT FiledDecember 23, 1988PCT Application Number:PCT/JP88/01296
PCT Publication Date:July 13, 1989PCT Publication Number: WO89/06130

International Patent Family for Patent: 5,034,230

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0348527► Subscribe
Denmark418889► Subscribe
Germany3882042► Subscribe
Australia610979► Subscribe
Australia2905689► Subscribe
JapanH01250321► Subscribe
JapanH0662417► Subscribe
South Korea920002329► Subscribe
World Intellectual Property Organization (WIPO)8906130► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Federal Trade Commission
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: